Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Conditions: Renal Cell Carcinoma, Clear Cell, Somatic Interventions: Drug: Fruquintinib and Everolimus Sponsors: Peking University First Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials